loader
Please Wait
Applying Filters...

Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Pridopidine, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Pridopidine

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass

    Bora Pharmaceuticals- Making success more certain.

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    2D Structure
    1. Also known as: 346688-38-8, 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine, 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine, Acr16, Acr-16, 4-(3-methylsulfonylphenyl)-1-propylpiperidine
    Molecular Formula
    C15H23NO2S
    Molecular Weight
    281.4  g/mol
    InChI Key
    YGKUEOZJFIXDGI-UHFFFAOYSA-N
    FDA UNII
    HD4TW8S2VK
    Pridopidine has been used in trials studying the treatment of Huntington's Disease.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-(3-methylsulfonylphenyl)-1-propylpiperidine
    2.1.2 InChI
    InChI=1S/C15H23NO2S/c1-3-9-16-10-7-13(8-11-16)14-5-4-6-15(12-14)19(2,17)18/h4-6,12-13H,3,7-11H2,1-2H3
    2.1.3 InChI Key
    YGKUEOZJFIXDGI-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C
    2.2 Other Identifiers
    2.2.1 UNII
    HD4TW8S2VK
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine

    2. 4-(3-methanesulfonylphenyl)-1-propylpiperidine

    3. Acr16 Compound

    4. Huntexil

    2.3.2 Depositor-Supplied Synonyms

    1. 346688-38-8

    2. 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine

    3. 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine

    4. Acr16

    5. Acr-16

    6. 4-(3-methylsulfonylphenyl)-1-propylpiperidine

    7. Hd4tw8s2vk

    8. Chembl596802

    9. Fr310826

    10. Unii-hd4tw8s2vk

    11. Acr16 Compound

    12. Acr 16

    13. Pridopidine [usan]

    14. Pridopidine [usan:inn]

    15. Pridopidine [mi]

    16. Pridopidine [inn]

    17. Pridopidine (usan/inn)

    18. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine

    19. Pridopidine [who-dd]

    20. Schembl166748

    21. Asp2314

    22. Dtxsid90188225

    23. Bdbm50308028

    24. Mfcd09835586

    25. Zinc22063703

    26. Akos015891431

    27. Db11947

    28. Ncgc00386586-01

    29. As-50146

    30. Hy-10684

    31. Db-014417

    32. Cs-0002733

    33. Ft-0672149

    34. 4-(3-methanesulfonylphenyl)-1-propylpiperidine

    35. D09953

    36. O11067

    37. Q7242858

    38. Piperidine, 4-(3-(methylsulfonyl)phenyl)-1-propyl-

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 281.4 g/mol
    Molecular Formula C15H23NO2S
    XLogP32.6
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count4
    Exact Mass281.14495015 g/mol
    Monoisotopic Mass281.14495015 g/mol
    Topological Polar Surface Area45.8 Ų
    Heavy Atom Count19
    Formal Charge0
    Complexity366
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for use/treatment in huntington's disease and schizophrenia and schizoaffective disorders.

    5 Pharmacology and Biochemistry
    5.1 Mechanism of Action

    ACR16 belongs to a novel class of drugs, characterised as dopaminergic stabilisers, CNS active compounds that can both enhance and counteract dopaminergic effects in the brain depending on the initial level of dopaminergic activity. ARC16 works to "smooth" the many functions of this neurotransmitter chemical in striatum and other areas of the brain. Thus they have the ability to stabilize behavioural and motor disturbances caused by neurological and psychiatric disorders. They do this in pathological states without compromising normal thought processes or motor functions.

    Post Enquiry
    POST ENQUIRY